Immunology/vaccines Infections and Infestations Vaccination again disease
Conditions
Interventions
Treatment group:
1. Mothers at 6 weeks: 200,000 IU Vitamin A x 2 (day 1 and day 2)
2. Infants at 6, 10 and 14 weeks: 50,000 IU Vitamin A and Diphtheria, Pertussis, Teta
Sponsors
World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Live-born infants 2. Willingness of mothers to participate in the study 3. Must reside in the study area for at least 4 months after the birth 4. Consent to two blood samples before and after their child's vaccination
Exclusion criteria
Exclusion criteria: Does not comply with above inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The impact of the different doses of vitamin A on the pentavalent vaccines will be assessed by comparing the two groups in terms of their seroconversion rates for: 1. Hepatitis B 2. Haemophilus influenzae type b The choice of four months for reevaluation is because this is the age at which it is presently recommended to determine the seroconversion rates. Accordingly, pre-samples will be taken at 6 weeks prior to DPT-HepB Hib immunisation and post samples will be taken at 1 month after the DPT-HepB Hib immunisation. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
Ghana, Switzerland
Outcome results
None listed